IPP Bureau
Zymo Research receives CE Mark for new Covid-19 SafeCollect kits
By IPP Bureau - September 01, 2021
Self-collection devices designed for ease of use and safety
Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
By IPP Bureau - September 01, 2021
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate
By IPP Bureau - September 01, 2021
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Metropolis Healthcare opens new testing centre in Thalassery, Kerala
By IPP Bureau - September 01, 2021
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
Two major hospitals in Gujarat announce tie-up
By IPP Bureau - September 01, 2021
Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot
Sher-I-Kashmir Institute of Medical Sciences and Medtronic partner to open Surgical Skills Lab
By IPP Bureau - September 01, 2021
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
By IPP Bureau - August 31, 2021
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184
By IPP Bureau - August 31, 2021
The drug is also intended for the treatment of glioblastoma multiforme
Sun Pharma to commercialise Winlevi in the US and Canada
By IPP Bureau - August 31, 2021
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
By IPP Bureau - August 31, 2021
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Dr. Reddy's announce launch two drugs in the US market
By IPP Bureau - August 31, 2021
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100
Vivo Bio Tech enters long-term contract with Bio E
By IPP Bureau - August 30, 2021
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Union Minister Sonowal announces major plans for promoting Ayush in NE
By IPP Bureau - August 30, 2021
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
Granules India receives approval from Health Canada for arthritis drug
By IPP Bureau - August 30, 2021
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
Acute therapies drive overall pharma growth in July: Ind-Ra
By IPP Bureau - August 30, 2021
The segment delivered strong sales growth of 20% YoY
